SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : corgenix

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: RikRichter5/14/2009 11:38:05 PM
   of 191
 
Good summary of today's conference call from Yahoo MB by a poster:

Short Term (1-6 months)

Good chance at profitability. Interest will be MUCH lower. Contract manufacturing is UP and it sounds like it could continue climbing. AW (AspirinWorks)sales up 10% over SPLY and CONX is going on sales calls with SpectraCell.

Mid-Term (6-12 months)

Driving towards a unique reimbursement code for AW. This would result in higher compensation to the labs and they would push the test harder. Collection of studies growing and provides ammunition for getting endorsement from key associations, which is the easy road to explosive growth.

Long Term (1 year+)

Product pipeline looks excellent for such a small company. Atherox progressing. NIH did a very unusual thing awarding five year contract for Lassa test because they think it is great. The key is to transform the test into one used in the field with NO LAB at all. This is key to bio-defense and to real value in Western Africa NASH detection via HA demonstrated good results in initial studies. They now need a second round of vetting for FDA 510 filing. The goal for HA is domestic testing for NASH.

Battelle relationship should be good in the longer term as CONX should play role in prototype development and production scale up. Battelle has some contract vehicles.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext